Back to Journals » Cancer Management and Research » Volume 12

Elevated Platelet Count Predicts Poor Prognosis in Breast Cancer Patients with Supraclavicular Lymph Node Metastasis

Authors Liu S, Fang J, Jiao D, Liu Z

Received 10 April 2020

Accepted for publication 8 July 2020

Published 20 July 2020 Volume 2020:12 Pages 6069—6075


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Antonella D'Anneo

Shaoqing Liu, Jing Fang, Dechuang Jiao, Zhenzhen Liu

Department of Breast Surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China

Correspondence: Zhenzhen Liu
Department of Breast Surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Tel +86 13603862755

Background: More and more studies show that platelets are closely related to the occurrence and development of tumors. This study aims to explore the predictive value of peripheral blood platelet count on the prognosis of breast cancer patients with ipsilateral supraclavicular lymph node (ISLN) metastasis.
Methods: Eighty-five breast cancer patients with ISLN metastasis in the Affiliated Cancer Hospital of Zhengzhou University were collected retrospectively in this study. Chi-square test was used to analyze the correlation between clinical pathological data and platelet count. DFS rate was estimated by K-M curve and Log Rank test was performed. Univariate and multivariate Cox regression were used to determine the prognostic value of platelets. Time-dependent Cox regression was used to further analyze the correlation between peripheral blood platelets and prognosis to determine the stability of the results.
Results: The pathological complete response rate of ISLN after neoadjuvant chemotherapy (NAC) was 51.8%. Platelet count was correlated with PR status of breast cancer at first visit (P=0.01). After a median follow-up of 30 months, multivariate Cox analysis showed that high platelet count (HR=3.18, 95% CI=1.13– 8.93, P=0.028), premenopausal status (HR=0.40, 95% CI=0.17– 0.97, P=0.043), and ISLN pathological failure (HR=0.25 95%, CI=0.10– 0.62, P< 0.01) were associated with poor prognosis. K-M curve analysis showed that the prognosis of patients with a high platelet count was worse than that of patients with low platelet count (HR=5.32, 95% CI=2.41– 11.75, P< 0.01). To further verify the stability of this result, multivariate time-dependent Cox model also suggested that higher platelet level was related to poor prognosis (HR=1.009, 95% CI=1.003– 1.016, P< 0.01). Meanwhile, menopausal status (HR=0.32, 95% CI=0.14– 0.76, P=0.01) and sPCR (HR=0.29, 95% CI=0.12– 0.70, P=0.01) were also independent predictors of DFS.
Conclusion: Platelets have important predictive value for the prognosis of breast cancer patients with ISLN metastasis, which indicates that platelet count can be used to distinguish high-risk patients so as to obtain clinical benefits.

Keywords: platelet, neoadjuvant chemotherapy, prognosis, ipsilateral supraclavicular lymph nodes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]